Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma.
Bajetta E, Del Vecchio M, Vitali M, Martinetti A, Ferrari L, Queirolo P, Sertoli MR, Cainelli T, Cellerino R, Cascinelli N. Bajetta E, et al. Among authors: cascinelli n. Tumori. 2001 Jul-Aug;87(4):219-22. doi: 10.1177/030089160108700402. Tumori. 2001. PMID: 11693798 Clinical Trial.
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
Sertoli MR, Queirolo P, Bajetta E, Del Vecchio M, Comella G, Barduagni L, Bernengo MG, Vecchio S, Criscuolo D, Bufalino R, Morabito A, Cascinelli N. Sertoli MR, et al. Among authors: cascinelli n. Melanoma Res. 1999 Oct;9(5):503-9. doi: 10.1097/00008390-199910000-00010. Melanoma Res. 1999. PMID: 10596917 Clinical Trial.
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, Taveggia P, Bernengo MG, Legha SS, Formisano B, Cascinelli N. Bajetta E, et al. Among authors: cascinelli n. Ann Oncol. 2006 Apr;17(4):571-7. doi: 10.1093/annonc/mdl007. Epub 2006 Feb 9. Ann Oncol. 2006. PMID: 16469753 Free article. Clinical Trial.
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchianò A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G. Belli F, et al. Among authors: cascinelli n. J Clin Oncol. 2002 Oct 15;20(20):4169-80. doi: 10.1200/JCO.2002.09.134. J Clin Oncol. 2002. PMID: 12377960 Clinical Trial.
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, Ravagnani F, Magni M, Chaplin P, Cascinelli N, Parmiani G, Gianni AM, Anichini A. Di Nicola M, et al. Among authors: cascinelli n. Clin Cancer Res. 2004 Aug 15;10(16):5381-90. doi: 10.1158/1078-0432.CCR-04-0602. Clin Cancer Res. 2004. PMID: 15328176 Clinical Trial.
S100 protein serum levels in cutaneous malignant melanoma.
Seregni E, Massaron S, Martinetti A, Illeni MT, Rovini D, Belli F, Agresti R, Greco M, Cascinelli N, Bombardieri E. Seregni E, et al. Among authors: cascinelli n. Oncol Rep. 1998 May-Jun;5(3):601-4. doi: 10.3892/or.5.3.601. Oncol Rep. 1998. PMID: 9538159
233 results